CLAIMS

1. Use of a ribonuclease that is a member of the ribonuclease A superfamily in the preparation of a pharmaceutical composition for the treatment of an adenoviral infection to the eye.

2. The use of claim 1, wherein the eye is a human eye and the ribonuclease is selected from a group consisting of:

a. ranpirnase;

b. the '805 variant;

c. Amphinase 2; and

d. rAmphinase 2.

3. The use of claim 1 or claim 2, wherein the ribonuclease is non-irritating to the eye as determined using

a. the Globally Harmonized System of Classification Evaluation Criteria, and

b. the European Economic Community Ocular Evaluation Criteria.

4. The use of claim 1, wherein the eye is a human eye and the ribonuclease is functionally equivalent to a ribonuclease selected from a group consisting of:

a. ranpirnase;

b. the '805 variant;

c. Amphinase 2; and

d. rAmphinase 2.

5. Use of:

a. a ribonuclease that is a member of the ribonuclease A superfamily and that is non-irritating to the eye as determined using

i. the Globally Harmonized System of Classification Evaluation Criteria, and

ii. the European Economic Community Ocular Evaluation Criteria; and

b. a vehicle,

in the preparation of an ophthalmic composition for the treatment of an adenoviral infection of the human eye..

6. Use of an ophthalmic composition to the eye, the composition comprising:

a. a therapeutically effective dose of a ribonuclease that is a member of the ribonuclease A superfamily and that is non-irritating to the eye as determined using

i. the Globally Harmonized System of Classification Evaluation Criteria, and

ii. the European Economic Community Ocular Evaluation Criteria; and

b. a vehicle,

in the preparation of a medicament for the treatment of an adenoviral infection of the human eye..

7. The use of claim 5 or claim 6, wherein the ribonuclease is selected from a group consisting of:

a. ranpirnase;

b. the '805 variant;

c. Amphinase 2; and

d. rAmphinase 2.

8. The use of any one of claims 5 to 7, wherein the vehicle is an aqueous solution.

9. The use of claim 5, claim 6 or claim 8, wherein the ribonuclease is the functional equivalent of a ribonuclease selected from a group consisting of:

a. ranpirnase;

b. the '805 variant;

c. Amphinase 2; and

d. rAmphinase 2.

10. Use of ranpirnase in the preparation of a pharmaceutical composition in the treatment of an adenoviral infection of an eye, wherein the composition is for topical administration.

11. The use according to claim 10, wherein the ranpirnase is a recombinant ranpirnase.

12. The use according to claim 10, wherein the ranpirnase is SEQ ID NO: 1 or SEQ ID NO: 2.

13. The use according to any one of claims 10 to 12, wherein the adenoviral infection is the cause of viral conjunctivitis, epidemic keratoconjunctivitis, or pharyngoconjuctival fever.

14. The use according to any one of claims 10 to 13, wherein the adenoviral infection is caused by an adenovirus 3, an adenovirus 4, an adenovirus 7, an adenovirus 8, an adenovirus 19, an adenovirus 29 or an adenovirus 37.

15. The use according to any one of claims 10 to 14, wherein the ranpirnase is formulated as an ophthalmic pharmaceutical composition.

16. The use according to claim 15, wherein the ophthalmic pharmaceutical composition is a solution, a suspension, a nanosuspension, an emulsion, a microemulsion, a nanoemulsion, an ointment, a gel, a hydrogel, liposomes, niosomes, nanoparticles, or dendrimers.

17. The use according to claim 15 or claim 16, wherein the ophthalmic pharmaceutical composition further comprises a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient.

18. The method according to any one of claims 10 to 17, wherein the ranpirnase is for administration as eye drops.

19. The use according to any one of claims 9 to 17, wherein the eye is from a human.